

CLAIMS

What is claimed is:

1. A composition comprising an isomerized variant of an anti-BCMA antibody, wherein the isomerized variant comprises a heavy chain amino acid sequence of SEQ ID NO: 9 or 11 and a light chain amino acid sequence of SEQ ID NO: 10; wherein the composition comprises 0.1-25% isomerized variant iso-D at position 103 at CDRH3 of the heavy chain.

2. The composition according to claim 1 wherein the composition comprises 0.1-40% oxidised variant oxi-M at position 34 at CDRH1 of the heavy chain.

3. The composition according to any preceding claim wherein the composition comprises $\leq 65\%$ oxidation at heavy chain M256 and/or $\leq 60\%$ oxidation at heavy chain M432.

4. The composition according to any preceding claim wherein the composition comprises an antibody variant comprising at least one selected from the group consisting of heavy chain deamidation at N388 and/or N393, D103 to N103 at CDRH3, C-terminal lysine cleavage, and N-terminal conversion of glutamine to pyroglutamic acid.

5. The composition according to any preceding claim wherein the composition comprises at least one selected from the group consisting of up to 100% deamidation at N388 and/or N393, up to 100% N103 at CDRH3, up to 100% C-terminal lysine cleavage, and up to 100% N-terminal conversion of glutamine to pyroglutamic acid.

6. The composition according to any preceding claim wherein the composition comprises any percentage of glycoforms G0, G1, G2, G0-GlcNac or G0-2GlcNac.

7. The composition according to any preceding claim wherein the anti-BCMA antibody is belantamab.

8. The composition according to any one of the preceding claims wherein the anti-BCMA antibody is conjugated to a cytotoxic agent to form an antibody-drug-conjugate.

9. The composition according to any one of the preceding claims wherein the anti-BCMA antibody is belantamab mafodotin.

10. The composition according to claims 8-9, wherein the percent DL2 is at least about 30%, about 15% to about 27%, or about 15% to about 32%; percent DL4a is at least about 30%, about 35% to about 38%, or about 30% to about 40%; percent DL4b is at least about 5%, about 7% to about 9%, or about 5% to about 10%; percent DL6 is at least about 10%, about 14% to about 20%, or about 10% to about 20%; and/or DL8 is at least about 1%, about 6.0% to about 12.0%, or about 4% to about 15%.

11. The composition according to claims 8-10, wherein the average DAR is about 2.1 to about 5.7.

12. The composition of claims 8-11, wherein percent DL0 is less than or equal to about 10% or about 5%.

13. A pharmaceutical composition comprising the composition of any preceding claim and at least one pharmaceutically acceptable excipient.

14. A formulation comprising the pharmaceutical composition of claim 13 comprising an anti-BCMA antigen binding protein at about 20 mg/mL to about 60 mg/mL, citrate buffer at about 10 mM to about 30 mM, trehalose at about 120 mM to about 240 mM, EDTA at about 0.01 mM to about 0.1 mM, polysorbate 20 or polysorbate 80 at about 0.01% to about 0.05%, at a pH of about 5.9 to about 6.5.

15. The composition of claims 1-12 or the pharmaceutical composition according to claim 13 for use in the treatment of cancer.

16. Use of the composition of claims 1-12 or the pharmaceutical composition according to claim 13 in the manufacture of a medicament for treatment of cancer.

17. The composition of claims 1-12 or the pharmaceutical composition according to claim 13 for use in medicine.